Endocrinology

Top Story

Short-term sitagliptin therapy preserves beta-cell function in women with PCOS, obesity

November 22, 2017

Among women with polycystic ovary syndrome and obesity participating in a lifestyle intervention, those who were assigned the DPP-IV inhibitor sitagliptin were less likely to progress to impaired glucose tolerance and type 2 diabetes than those assigned placebo, study data show.

Mojca Jensterle, MD, PhD, of the department of endocrinology, diabetes and metabolic disease at the University Medical Centre Ljubljana in Slovenia, and colleagues evaluated women (mean age, 35 years) with PCOS and obesity (mean BMI, 36.9 kg/m2) who were metformin-intolerant and randomly assigned to a lifestyle intervention plus 100 mg daily sitagliptin (Januvia, Merck; n = 15) or lifestyle intervention alone (n = 13) for 12 weeks. Researchers sought to determine whether sitagliptin plus lifestyle intervention preserves beta-cell function.

In the Journals Plus

Joint endocrinologist-nephrologist clinic reduced diabetic kidney disease progression

November 22, 2017
Patients with type 2 diabetes and stage 3 or 4 chronic kidney disease who attended a joint endocrinologist-nephrologist diabetic kidney disease clinic were less likely…
In the Journals PlusPerspective

Despite declines in sugar-sweetened beverage intake, consumption stable among Hispanics

November 22, 2017
Sugar-sweetened beverage intake in the United States declined between 2003 and 2014 in both children and adults, but consumption rates remained steady among…

BLOG: November, again!

November 21, 2017
On Nov. 21, 2016, we launched this blog on Healio.com/Endocrinology. We mutually agreed to call the blog, “From the Doctor’s Bag.” On the occasion of…
In the Journals Plus

Bone loss remains elevated 5 years after RYGB vs. sleeve gastrectomy

November 21, 2017
Adults with uncontrolled type 2 diabetes and obesity treated with Roux-en-Y gastric bypass surgery vs. sleeve gastrectomy or intensive medical therapy had elevated bone…
More Headlines »
CNE CME CPE

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Video
Meeting News

VIDEO: Public’s reliance on Google costs physicians time with patients

November 1, 2017
More »
Resource Centers
ObesityWeek

ObesityWeek

ABIM MOC CME

Ace the Case: A 39-Year-Old Man with Progressive Weight Gain

No commercial support for this activity.

This “Ace the Case” activity will use a case study to discuss obesity management in a patient with progressive weight…
More »
Current Issues
View the Current Issue
Advertisement
Advertisement